ALK boss on surprising bottom line: "The underlying operations are getting better and better"

Carste Hellmann, CEO of ALK, is excited about the company's financial report, where earnings in particular were a positive surprise. The difference between deficit and profit depends on how much the company spends on clinical trials from now on, he says.

Carsten Hellmann, CEO of ALK, is proud that the company has delivered 11 percent revenue growth and a better than expected bottom line. Photo: Gregers Tycho / Ritzau / Ritzau Scanpix

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles